Kitagawa, K.; Moriya, K.; Kaji, K.; Saikawa, S.; Sato, S.; Nishimura, N.; Namisaki, T.; Akahane, T.; Mitoro, A.; Yoshiji, H.
Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. Int. J. Mol. Sci. 2020, 21, 7588.
https://doi.org/10.3390/ijms21207588
AMA Style
Kitagawa K, Moriya K, Kaji K, Saikawa S, Sato S, Nishimura N, Namisaki T, Akahane T, Mitoro A, Yoshiji H.
Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. International Journal of Molecular Sciences. 2020; 21(20):7588.
https://doi.org/10.3390/ijms21207588
Chicago/Turabian Style
Kitagawa, Koh, Kei Moriya, Kosuke Kaji, Soichiro Saikawa, Shinya Sato, Norihisa Nishimura, Tadashi Namisaki, Takemi Akahane, Akira Mitoro, and Hitoshi Yoshiji.
2020. "Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells" International Journal of Molecular Sciences 21, no. 20: 7588.
https://doi.org/10.3390/ijms21207588
APA Style
Kitagawa, K., Moriya, K., Kaji, K., Saikawa, S., Sato, S., Nishimura, N., Namisaki, T., Akahane, T., Mitoro, A., & Yoshiji, H.
(2020). Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. International Journal of Molecular Sciences, 21(20), 7588.
https://doi.org/10.3390/ijms21207588